Back to search
FDAFDA · Food and drugs·Recall number Z-0168-2015

COMPASS, Model No. SW Version 3.1, catalogue number CS10-100 (medical Linear accelerator) radiological

Published November 12, 2014 · Recall initiated: September 25, 2014

Summary

FDA records medical device Class II recall Z-0168-2015, published November 12, 2014 and initiated September 25, 2014. Recalling firm: Iba Dosimetry Gmbh; Status: Terminated; Reported quantity: 124 units. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Error in the software. A deviation between reconstructed and planned dose distribution may not be detected prior to treatment and this can result in an over or under-estimation of the pretreatment delivered dose.

What to do

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Iba Dosimetry Gmbh
Distributor
Worldwide Distribution-Distributed in the US including Guam and the countries of Germany, Austria, France, UK, Poland, Finland, The Netherlands, Spain, Turkey, Russia, and South Africa, Algeria, Mexico, Brazil, Venezuela, Columbia, Panama, China, Japan Philippines, Korea, India, Singapore, Thailand, Taiwan, Hong Kong, and Malaysia.
Risk classification
Class II
Area (FDA)
device
Country
Germany

Related recalls

Questions about this recall

Was COMPASS, Model No. SW Version 3.1, catalogue number CS10-100 (medical Linear accelerator) radiological recalled?

Yes. FDA published recall Z-0168-2015 on November 12, 2014. Reported hazard: Error in the software. A deviation between reconstructed and planned dose distribution may not be detected prior to treatment and this can result in an over or under-estimation of the pretreatment delivered dose.

What should I do if I have this product?

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit